eFFECTOR Therapeutics (NASDAQ:EFTR) Stock Price Up 2%

Posted by Defense World Staff on May 19th, 2023

Shares of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR – Get Rating) traded up 2% during mid-day trading on Thursday . The stock traded as high as $0.68 and last traded at $0.65. 293,493 shares traded hands during mid-day trading, a decline of 8% from the average session volume of 318,152 shares. The stock had previously closed at $0.64.

Wall Street Analyst Weigh In

Separately, Credit Suisse Group dropped their price target on eFFECTOR Therapeutics from $8.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, March 9th.

eFFECTOR Therapeutics Stock Up 2.0 %

The company’s 50-day moving average is $0.43 and its two-hundred day moving average is $0.47. The company has a market cap of $27.57 million, a P/E ratio of -0.76 and a beta of 0.36.

eFFECTOR Therapeutics (NASDAQ:EFTR – Get Rating) last released its earnings results on Wednesday, March 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04). The business had revenue of $0.67 million for the quarter. On average, analysts anticipate that eFFECTOR Therapeutics, Inc. will post -0.74 EPS for the current fiscal year.

Hedge Funds Weigh In On eFFECTOR Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of EFTR. State Street Corp bought a new stake in shares of eFFECTOR Therapeutics in the first quarter valued at $68,000. Renaissance Technologies LLC bought a new stake in eFFECTOR Therapeutics in the 2nd quarter valued at about $42,000. Two Sigma Investments LP purchased a new stake in eFFECTOR Therapeutics during the third quarter valued at about $27,000. Sea Otter Advisors LLC purchased a new stake in eFFECTOR Therapeutics during the first quarter valued at about $93,000. Finally, CI Private Wealth LLC bought a new position in eFFECTOR Therapeutics during the fourth quarter worth about $118,000. 68.71% of the stock is owned by institutional investors.

eFFECTOR Therapeutics Company Profile

(Get Rating)

eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.